Medigen Vaccine Biologics
TWSE:4162Taipei, Taiwan· Est.
Taiwanese vaccine maker delivering approved Enterovirus A71 vaccine and expanding into broader infectious‑disease markets.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileAI Company Overview
Taiwanese vaccine maker delivering approved Enterovirus A71 vaccine and expanding into broader infectious‑disease markets.
Infectious DiseasesVaccines
Technology Platform
Inactivated whole‑virus vaccine platform using aluminum‑phosphate adjuvant for rapid, scalable, and cost‑effective production of pediatric vaccines.
Opportunities
Geographic expansion into Southeast Asian markets and development of additional pediatric vaccines leveraging existing manufacturing capacity.
Risk Factors
Regulatory hurdles in new markets, reliance on a single commercial product, and competition from larger multinational vaccine manufacturers.
Competitive Landscape
Few competitors have comparable efficacy data for EV‑A71; Medigen differentiates through proven clinical results, regional partnerships, and cost‑effective production.